LUCIDITY data suggest that participants receiving hydromethylthionine mesylate (HMTM) decline at a rate substantially less than is typical in Alzheimer's based on published research
Safety profile is favourable and consistent with previous HMTM studies
TauRx will now pursue regulatory submission and coverage for HMTM
SINGAPORE, June 1, 2022 /PRNewswire/ --TauRx Pharmaceuticals Ltd, the global leader in tau-based research in Alzheimer's, today announced unblinding of initial data from completion of the randomised portion of their pivotal Phase 3 clinical trial, LUCIDITY (NCT03446001).
